 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Diabetes
In diabetes, there are elevated blood sugar levels due to absolute or relative insufficiencies of insulin. There are two types of diabetes: type 1 (previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes) and type 2 (previously called non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes). There are signs that type 2 diabetes is being diagnosed more often in adolescents and young adults, due to sedentary lifestyles and 'fast-food' eating habits. Most type 2 diabetics produce variable, even normal, amounts of insulin, but have abnormalities in liver and muscle cells that resist its action.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
ALTITUDE Diabetes Study CSPP100E2337
The purpose of this clinical research study is to determine if the investigational drug aliskiren delays or prevents the occurrence of heart and/or kidney complications in participants with type 2 diabetes who are taking medications for heart and/or kidney problems. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3 Participation Duration: Depending on when participants join this study, their participation may last for two to four years with up to 23 scheduled visits. Protocol Number: CSPP100E2337 Diabetes Study CLMF237A2309
The purpose of this clinical research trial is to assess the safety and effectiveness of a fixed combination of vildagliptin and metformin for the treatment of participants with type 2 Diabetes.
Eligible participants must be on a stable dose of metformin, used consistently during the last 3 months.
Vildagliptin is considered an investigational drug. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Metformin is already approved by the US Food and Drug Administration (FDA) and is available for sale in the U.S.
Trial phase: Phase 3b Participation Duration: Participants will be required to visit the study center 8 times over 28 weeks. Protocol Number: CLMF237A2309
Diabetes Study CLAF237A 23138
The purpose of this study is to determine if an investigational drug is safe to lower blood sugar in patients with diabetic nephropathy. Diabetic Nephropathy is a term used to describe kidney disease that occurs as a result of diabetes. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3b Participation Duration: The study will up to take up to 26 weeks (6 months 2 weeks). The participant will be required to visit the study center at least 9 times. After completing the study, participants may be asked to join a study extension. Protocol Number: CLAF237A 23138 |
